Sign in
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Journal article   Open access  Peer reviewed

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Christine M Lovly, Nerina T McDonald, Heidi Chen, Sandra Ortiz-Cuaran, Lukas C Heukamp, Yingjun Yan, Alexandra Florin, Luka Ozretić, Diana Lim, Lu Wang, …
Nature medicine, Vol.20(9), pp.1027-1034
2014-09
PMCID: PMC4159407
PMID: 25173427

Abstract

Lung Neoplasms - drug therapy Receptor, IGF Type 1 - metabolism Up-Regulation Pyrazoles - therapeutic use Lung Neoplasms - enzymology Humans Lung Neoplasms - metabolism Middle Aged Receptor Protein-Tyrosine Kinases - drug effects Gene Knockdown Techniques Receptor, IGF Type 1 - drug effects Female Pyridines - pharmacology Insulin Receptor Substrate Proteins - genetics Pyrazoles - pharmacology Pyridines - therapeutic use
url
https://doi.org/10.1038/nm.3667View
Published (Version of record) Open

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.199 Lung Cancer
1.199.581 NSCLC
Web Of Science research areas
Biochemistry & Molecular Biology
Cell Biology
Medicine, Research & Experimental
ESI research areas
Molecular Biology & Genetics

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details